Involvement of the ABCB1 C3435T Variant but Not the MTHFR C677T or MTHFR A1298C Variant in High-Dose Methotrexate-Induced Toxicity in Pediatric Acute Lymphoblastic Leukemia Patients in China
Qie Guo,Jia-Lin Sun,Ran Li,Xiao Li
DOI: https://doi.org/10.2147/ijgm.s453394
IF: 2.145
2024-03-28
International Journal of General Medicine
Abstract:Qie Guo, 1 Jia-Lin Sun, 1 Ran Li, 2 Xiao Li 1 1 Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, People's Republic of China; 2 Department of Infectious Diseases, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, People's Republic of China Correspondence: Xiao Li, Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, Shandong, 266003, People's Republic of China, Tel/Fax +86 53 82912263, Email Purpose: It remains unclear whether the MTHFR C677T, MTHFR A1298C and ABCB1 C3435T genetic variants are associated with methotrexate (MTX) elimination delay and high-dose MTX (HD-MTX) toxicities in the treatment of pediatric acute lymphoblastic leukemia (ALL). The aim of our study was to analyze the potential predictive role of MTHFR C677T, MTHFR A1298C and ABCB1 C3435T in toxicities and the relationship between these variants and MTX elimination delay during HD-MTX therapy in pediatric ALL patients. Patients and Methods: We conducted a retrospective study on ALL patients receiving HD-MTX treatment with available MTHFR C677T, MTHFR A1298C and ABCB1 C3435T genotype and 44-h plasma MTX levels. Logistic regression analyses and chi-square tests were used to assess the relationship between the variants and HD-MTX toxicities and MTX elimination delay. Results: Genotype frequencies were in Hardy-Weinberg equilibrium. MTX elimination delay did not significantly differ between MTHFR C677T and MTHFR A1298C or ABCB1 C3435T . Leukopenia (P=0.028), neutropenia (P=0.034) and oral mucositis (P=0.023) were 6.444-fold, 4.978-fold and 9.643-fold increased, respectively, in ABCB1 C3435T homozygous genotype ( TT ) patients compared to wild-type ( CC ) patients. No significant association was found between the toxicities investigated and MTHFR C677T or MTHFR A1298C . Conclusion: This study showed that the ABCB1 C3435T homozygous allele genotype ( TT ) is associated with increased MTX-related toxicities (leukopenia, neutropenia and oral mucositis). These results may help to distinguish pediatric ALL patients with a relatively high risk of MTX-related toxicities before HD-MTX infusion and optimize MTX treatment. Keywords: high-dose methotrexate toxicities, MTHFR C677T and MTHFR A1298C genetic variants, ABCB1 C3435T genetic variant, MTX elimination delay, acute lymphoblastic leukemia Acute lymphoblastic leukemia (ALL) is a common malignancy in children. 1 Methotrexate (MTX), which can induce a low level of folate, affects the intracellular folate pool and influences the activity of the enzyme methylenetetrahydrofolate reductase ( MTHFR ), is an important drug for treatment of children with ALL. 2–5 Although high-dose MTX (HD-MTX) with enhanced antineoplastic activity has achieved remarkable clinical success in treatment of children with ALL, unpredictable toxicities continue to challenge its clinical use. 6 Our previous study identified clinical predictors from among patient characteristics (eg, age, sex, body surface area, subtype of leukemia, complete blood counts and liver function tests) for the occurrence of severe toxicities during HD-MTX therapy in children with ALL. 3 Some studies have also shown that chemotherapeutic agent-related toxicities vary with polymorphism frequency. 7,8 Overall, the identification of genetic predictors for MTX-induced toxicities would be valuable for selecting patients who may benefit from personalized treatment strategies. MTHFR gene polymorphism is critical in intracellular folate homeostasis and metabolism. 9 There are two well-characterized MTHFR polymorphisms: (1) a transition from a C to a T at nucleotide 677 ( C677T , rs1801133), which results in an increased level of homocysteine, decreasing enzymatic activity and altering folate distribution, 10 and (2) a transition from an A to C nucleobase at position 1298 ( A1298C , rs1801131), which results in reduced MTHFR activity. 11 Several published clinical reports conclude that risks of HD-MTX toxicities in treatment of children with ALL are associated with MTHFR C677T or MTHFR A1298C . 1,5,8,12–20 However, other studies have reported the opposite conclusions, namely, that there is no significant relationship between MTHFR C677T or MTHFR A1298C and HD-MTX toxicities. 4,21–24 Therefore, the potential predictive role of MTHFR C -Abstract Truncated-
medicine, general & internal